Posts for Gilead Sciences Inc ($GILD)

Gilead Sciences, Inc. (GILD) files an 8-K report detailing significant events on October 6, 2025. Essential for investors and analysts tracking NASDAQ updates.

Discover how the Trump-Pfizer agreement ignited a stock rally, boosting pharma stocks. Explore investment opportunities in $PFE, $MRNA, $JNJ, $GILD, and $ABBV amidst market uncertainties.

Explore the impact of emerging drug pricing policies on major pharmaceutical stocks like Pfizer, J&J, and Moderna. Stay informed to navigate market shifts effectively.

Discover Gilead Sciences' significant 8-K filing dated August 10, 2025. Stay informed on crucial developments impacting stock GILD and shareholder interests.

Explore Gilead Sciences' Q2 2025 financial report showcasing revenue growth in HIV therapy. Key insights on profitability, expenses, and market outlook for informed investment decisions.

Explore Gilead Sciences, Inc.'s 8-K report detailing significant corporate changes and events affecting investors as of August 7, 2025. Stay informed on GILD's latest developments.

Discover Gilead Sciences, Inc.'s latest 8-K filing revealing significant shareholder updates as of July 30, 2025. Stay informed on GILD stock and financial transparency.

Explore how recent economic indicators, like the jobs report, affect stocks of key companies like Tesla, Apple, and Broadcom. Stay informed for smart investment decisions.

Explore the impact of geopolitical events, like the Trump-Musk feud, on stocks like Tesla, Ford, and more. Stay informed on market fluctuations and investment strategies.

Foreign investors are pulling back from U.S. debt, impacting capital flow and stock valuations. Explore how this trend affects major players like BlackRock, Wells Fargo, and fintech firms.

Explore Gilead Sciences' 8-K filing detailing significant events on May 7, 2025. Stay informed on market implications for GILD shareholders.

Explore Gilead Sciences' Q1 2025 financial report, highlighting $6.647B revenue, $1.315B net income, and a positive outlook for investors. Key insights on profitability and R&D investments.